Blog Category

Scientific

Biophytis to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity

, ,

/

9 September 2026

Biophytis announces new non-clinical data further supporting its mission to pioneer the restoration of mobility in patients with obesity

,

/

24 March 2025

Biophytis revolutionizes sarcopenia

,

/

17 March 2025

Biophytis showcased the OBA program in obesity at the 17th SCWD international congress

,

/

23 December 2024

Presentation of Prof. Capucine Morelot-Panzini on 20E (BIO101) for Severe COVID-19 at the ERS 2024 Conference in Vienna

,

/

25 September 2024

JULY 1st, 2024

,

/

1 July 2024

Biophytis presented its phase 3 protocol in the treatment of sarcopenia

,

/

22 March 2024

Biophytis presented the potential of Ruvembriâ„¢ in the treatment of Duchenne Muscular Dystrophy

,

/

8 March 2024

Webcast of 17 January 2024 on our ambitions with Ruvembri® in respiratory viral infections

,

/

23 January 2024

Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet

, , ,

/

4 January 2024

Biophytis reports clinical results for Sarconeos (BIO101) in sarcopenia treatment at the 16 th SCWD International Congress

,

/

19 June 2023

Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference

,

/

25 May 2023